Background: Antiretrovirals are expensive and people living with HIV may experience a
range of financial burdens when accessing these medications. Our aim was to describe the …

Background Commentaries on the adequacy of insurance coverage for prescription drugs
available to Canadians have emphasized differences in the coverage provided by different …

The HIV/AIDS epidemic continues to be a critical public health issue in the United States,
where an estimated 1.2 million individuals live with HIV infection. Viral suppression is one of …

Background: Insurance coverage facilitates access to life-saving medications for many
patients with HIV disease. Thus, the effects of insurance coverage changes, such as the gain …

Background HIV/AIDS incidence and mortality rates have decreased in the US since 1996.
Accompanying the longer life spans of those diagnosed with the disease, however, is a …

The purpose of this study is to determine drug costs and the sociodemographic and clinical
determinants of drug costs in a large open cohort of HIV—positive adult men and women in …

Background Through delayed HIV disease progression, highly active antiretroviral therapy
(HAART) may reduce direct medical costs, thus at least partially offsetting therapy costs …

Importance The 2019 federal Ending the HIV Epidemic initiative requires a vast expansion of
access to antiretroviral therapy (ART) and preexposure prophylaxis (PrEP) for HIV treatment …

Background: Increased coverage with antiretroviral therapy for people living with HIV in low-
and middle-income countries has increased their life expectancy associated with non-HIV …

Drug formularies Provincial and territorial governments in Canada have a direct influence on
the provision of prescription drugs by establishing drug formularies, negotiating drug prices …